Sagimet Biosciences Future Growth
Future criteria checks 0/6
Sagimet Biosciences's earnings are forecast to decline at 31.5% per annum while its annual revenue is expected to grow at 88% per year. EPS is expected to decline by 24% per annum.
Key information
-31.5%
Earnings growth rate
-24.0%
EPS growth rate
| Biotechs earnings growth | 34.9% |
| Revenue growth rate | 88.0% |
| Future return on equity | n/a |
| Analyst coverage | Low |
| Last updated | 04 Oct 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | N/A | -183 | N/A | N/A | 4 |
| 12/31/2025 | N/A | -119 | N/A | N/A | 5 |
| 12/31/2024 | N/A | -48 | N/A | -58 | 5 |
| 6/30/2024 | 2 | -29 | -23 | -23 | N/A |
| 3/31/2024 | 2 | -28 | -23 | -23 | N/A |
| 12/31/2023 | 2 | -28 | -24 | -24 | N/A |
| 9/30/2023 | 2 | -27 | -24 | -24 | N/A |
| 6/30/2023 | N/A | -28 | -26 | -26 | N/A |
| 3/31/2023 | N/A | -28 | -27 | -27 | N/A |
| 12/31/2022 | N/A | -30 | -24 | -24 | N/A |
| 12/31/2021 | N/A | -24 | -22 | -22 | N/A |
| 12/31/2020 | N/A | -11 | -10 | -10 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 0O2 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 0O2 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 0O2 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: 0O2 is forecast to have no revenue next year.
High Growth Revenue: 0O2 is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 0O2's Return on Equity is forecast to be high in 3 years time